Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy
- PMID: 24481111
- DOI: 10.1161/CIRCHEARTFAILURE.113.000665
Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy
Abstract
Background: In hypertrophic cardiomyopathy (HCM), accumulation of myocardial collagen may play a central role in the pathogenesis of diastolic dysfunction and arrhythmia. Previous studies have suggested that peripheral levels of byproducts of collagen synthesis are reflective of myocardial extracellular matrix metabolism, although this has not been validated in detail. Given the potential clinical utility of such biomarkers, we sought to validate the assumed relationship between peripheral markers and myocardial fibrosis in HCM.
Methods and results: Fifty patients with HCM and 25 healthy controls underwent peripheral venous sampling to determine plasma concentrations of key collagen precursors (procollagen I and III N-terminal propeptides [PINP, PIIINP]). Contrast-enhanced cardiac magnetic resonance imaging was performed to quantify regional (by late-gadolinium enhancement) and diffuse (by T1 mapping) myocardial fibrosis. Nineteen subjects also underwent simultaneous arterial and coronary sinus blood sampling (to derive transcardiac concentration gradients of PINP, PIIINP, and C-terminal telopeptide of type I collagen) and right heart catheterization. Despite cardiac magnetic resonance evidence of regional (late-gadolinium enhancement quantity, 6.4±8.0%) and diffuse (T1 time, 478±79 ms) myocardial fibrosis in patients with HCM, peripheral levels of collagen precursors were similar compared with control subjects (PINP, 45.9±22.9 versus 53.4±25.9 μg/L; P=0.21; PIIINP, 4.8±1.7 versus 4.4±1.1 μg/L; P=0.26). No significant net positive transcardiac concentration gradient was detected for either biomarker of collagen synthesis.
Conclusions: The cardiac contribution to peripheral levels of byproducts of collagen synthesis in patients with HCM is insignificant. Furthermore, peripheral levels of these biomarkers do not accurately reflect myocardial collagen content in these patients.
Keywords: cardiomyopathy, hypertrophic; collagen; endomyocardial fibrosis; magnetic resonance imaging.
Comment in
-
What is measured by cardiac fibrosis biomarkers and imaging?Circ Heart Fail. 2014 Mar 1;7(2):239-42. doi: 10.1161/CIRCHEARTFAILURE.114.001156. Circ Heart Fail. 2014. PMID: 24643887 No abstract available.
Similar articles
-
Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure.Eur J Heart Fail. 2013 Mar;15(3):292-8. doi: 10.1093/eurjhf/hfs179. Epub 2012 Nov 9. Eur J Heart Fail. 2013. PMID: 23143794
-
Circulating collagen metabolites, myocardial fibrosis and heart failure in aortic valve stenosis.J Heart Valve Dis. 2013 Mar;22(2):166-76. J Heart Valve Dis. 2013. PMID: 23798204
-
Myocardial collagen turnover in hypertrophic cardiomyopathy.Circulation. 2003 Sep 23;108(12):1455-60. doi: 10.1161/01.CIR.0000090687.97972.10. Epub 2003 Sep 2. Circulation. 2003. PMID: 12952838 Clinical Trial.
-
Feasibility and significance of preclinical diagnosis in hypertrophic cardiomyopathy.Cardiol Rev. 2015 Nov-Dec;23(6):297-302. doi: 10.1097/CRD.0000000000000076. Cardiol Rev. 2015. PMID: 26440533 Review.
-
[Utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy: when is it superior to echocardiography?].Ann Cardiol Angeiol (Paris). 2015 Feb;64(1):9-13. doi: 10.1016/j.ancard.2014.04.015. Epub 2014 Apr 26. Ann Cardiol Angeiol (Paris). 2015. PMID: 24834991 Review. French.
Cited by
-
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.Clin Res Cardiol. 2018 Jan;107(1):49-59. doi: 10.1007/s00392-017-1157-3. Epub 2017 Aug 29. Clin Res Cardiol. 2018. PMID: 28852839 Clinical Trial.
-
Redefining the identity of cardiac fibroblasts.Nat Rev Cardiol. 2017 Aug;14(8):484-491. doi: 10.1038/nrcardio.2017.57. Epub 2017 Apr 24. Nat Rev Cardiol. 2017. PMID: 28436487 Free PMC article. Review.
-
Early segmental relaxation abnormalities in hypertrophic cardiomyopathy for differential diagnostic of patients with left ventricular hypertrophy.Clin Cardiol. 2017 Nov;40(11):1026-1032. doi: 10.1002/clc.22761. Epub 2017 Jul 24. Clin Cardiol. 2017. PMID: 28741295 Free PMC article.
-
Matrisome remodeling in the myocardium of hypertrophic cardiomyopathy; novel targets for molecular diagnostics.Front Cell Dev Biol. 2025 Aug 6;13:1641584. doi: 10.3389/fcell.2025.1641584. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40843168 Free PMC article. Review.
-
Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player.Ann Transl Med. 2016 Dec;4(24):548. doi: 10.21037/atm.2016.12.01. Ann Transl Med. 2016. PMID: 28149909 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources